Diasys Diagnostic Systems Gmbh Pharmaceutical Import Profile — Germany (DGFT 2022–2026)

Name: Diasys Diagnostic Systems Gmbh Pharmaceutical Import Records from India — 4 Products, $2.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Diasys Diagnostic Systems Gmbh — Pharmaceutical Importer Profile (2026) | 4 Products, $2.5M Trade | TransData Nexus

Diasys Diagnostic Systems Gmbh

Pharmaceutical Importer · Germany · Medical Devices & Diagnostics Focus · $2.5M Total Trade · DGFT Verified

Diasys Diagnostic Systems Gmbh is a pharmaceutical importer based in Germany with a total trade value of $2.5M across 4 products in 3 therapeutic categories. Based on 123 verified import shipments from Indian Customs (DGFT) records, Diasys Diagnostic Systems Gmbh is the #1 buyer in 1 product including Reagent. Diasys Diagnostic Systems Gmbh sources from 1 verified Indian supplier, with Advy Chemical Private Limited accounting for 100.0% of imports.

Diasys Diagnostic Systems Gmbh — Import Portfolio & Supplier Network

Diasys Diagnostic Systems Gmbh import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Diasys Diagnostic Systems Gmbh?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Advy Chemical Private Limited	$824.4K	56	100.0%

Diasys Diagnostic Systems Gmbh sources from 1 verified Indian supplier across 41 distinct formulations. The sourcing is highly concentrated — Advy Chemical Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Diagnostic reagents goat anti human apolipoprotein a1 fractionated goat antiserum for use in in vitro diagnostic	$100.0K	2
Diagnostic reagents goat anti human crp whole serum goat antiserum for use in in vitro diagnostic reagent for	$97.2K	2
Diagnostic reagents goat anti-human	$50.0K	3
Diagnostic reagents goat anti- human	$50.0K	1
Diagnostic reagents goat anti- human	$50.0K	1
Diagnostic reagents goat anti-human apolipoprotein b, whole serum (goat antiserum for use in in-vitro	$50.0K	1
Diagnostic reagents goat anti- human pre-albumin whole serum (goat antiserumfor use in in-vitro diagnostic reagent	$50.0K	1
Diagnostic reagents goat anti- human apolipoprotein a1, fractionated(goat antiserum for use in in-vitro	$50.0K	1
Diagnostic reagents for medicinal products goat anti- human pre-albumin, whole serum (goat antiserum for use in	$50.0K	2
Goat anti- human crp, whole serum (goat antiserum for use in in-vitro diagnostic reagent for determination of	$50.0K	1
Goat anti- human crp, whole serum (goat antiserum for use in in-vitro diagnostic reagent for determination	$49.0K	1
Diagnostic reagents goat anti-human	$46.7K	2
Diagnostic reagents goat anti- human crp, whole serum (goat antiserum for use in in-vitro diagnostic	$20.8K	2
Diagnostic reagents goat anti- human	$18.6K	5
Diagnostic reagents goat anti-human igg (fc), whole serum (goat antiserum foruse in in-vitro diagnostic reagent for	$12.5K	1

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Diagnostic	Medical Devices & Diagnostics	$950.5K	53	5.2%	2
2	Reagent	Medical Devices & Diagnostics	$950.5K	51	7.2%	1
3	Serum	Other	$339.0K	12	1.2%	18
4	Protein	Nutritional Supplements	$280.1K	7	1.9%	7

Diasys Diagnostic Systems Gmbh imports 4 pharmaceutical products across 3 categories into Germany totaling $2.5M. The company is the #1 buyer for 1 product: Reagent.

Diasys Diagnostic Systems Gmbh — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

DiaSys Diagnostic Systems GmbH, established in 1991, is a German company specializing in the development, manufacturing, and marketing of diagnostic systems for clinical laboratories. Headquartered in Holzheim, Rhineland-Palatinate, Germany, the company has grown to employ between 200 and 500 individuals. DiaSys offers a comprehensive portfolio that includes over ninety liquid-stable reagents for routine and special diagnostics, complemented by calibrators and controls. Their instrumentation range features both partially and fully automated analyzers tailored for small and medium-sized laboratories, as well as devices and rapid tests for point-of-care applications.

In December 2023, DiaSys became a majority-owned subsidiary of Shenzhen Mindray Bio-Medical Electronics Co., Ltd., which acquired a 75% stake in the company. This strategic acquisition aims to enhance Mindray's global competitive edge in the in-vitro diagnostics sector by integrating DiaSys's expertise and expanding its international presence.

2Distribution Network

DiaSys Diagnostic Systems GmbH operates a global distribution network, ensuring its diagnostic products reach laboratories, hospitals, and physicians in over 140 countries. While specific details about their warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive international reach indicates a well-established and efficient supply chain infrastructure. The integration with Mindray is expected to further strengthen and expand this distribution network, leveraging Mindray's existing global logistics and support systems.

3Industry Role

Within Germany's pharmaceutical supply chain, DiaSys Diagnostic Systems GmbH functions primarily as a manufacturer and supplier of diagnostic reagents and systems. Their role is distinct from that of pharmaceutical importers or wholesalers, as they focus on providing diagnostic solutions rather than pharmaceutical products. The company's products are integral to clinical laboratories, supporting the diagnosis and monitoring of various health conditions. Their position in the supply chain is crucial for ensuring the availability of high-quality diagnostic tools essential for patient care.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Diasys Diagnostic Systems Gmbh

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

DiaSys Diagnostic Systems GmbH's sourcing strategy appears to be highly concentrated, with a significant portion of their imported products originating from a single supplier, ADVY Chemical Private Limited. This single-source dependency could pose risks related to supply chain disruptions, such as production delays or quality control issues. However, the consistent volume of shipments—56 shipments totaling $824,000—suggests a stable and long-term relationship between DiaSys and ADVY Chemical. This stability may mitigate some of the risks associated with sourcing from a single supplier. Nonetheless, it would be prudent for DiaSys to consider diversifying its supplier base to enhance supply chain resilience and reduce potential vulnerabilities.

2Supply Chain Resilience

The resilience of DiaSys Diagnostic Systems GmbH's supply chain, particularly concerning their Indian supplier, ADVY Chemical Private Limited, is not fully transparent. The lack of publicly available information about backup suppliers and the diversity of formulations imported makes it challenging to assess the robustness of their supply chain comprehensively. Additionally, without detailed insights into shipping routes and the regulatory compliance status of key suppliers, it's difficult to evaluate potential exposure to disruptions. To strengthen supply chain resilience, DiaSys may consider diversifying its supplier base and enhancing transparency regarding its sourcing strategies.

Importing Pharmaceuticals into Germany — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Germany

1Regulatory Authority & Framework

In Germany, the primary regulatory authority overseeing pharmaceutical imports is the Federal Institute for Drugs and Medical Devices (BfArM). The key legislation governing pharmaceutical imports includes the German Medicines Act (AMG), which outlines the requirements for the importation, distribution, and marketing of medicinal products. For Indian generics to be marketed in Germany, they must undergo a marketing authorization process, which involves demonstrating bioequivalence to the reference product and compliance with Good Manufacturing Practice (GMP) standards. The European Medicines Agency (EMA) provides centralized procedures for marketing authorization, but national procedures may also apply.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Germany are stringent. Importers must hold a wholesale distribution authorization issued by the BfArM. Additionally, imported products must be manufactured in facilities that comply with EU GMP standards. Recognition of GMP certificates from other jurisdictions, such as WHO GMP or PIC/S, is possible but requires a thorough evaluation to ensure equivalence with EU standards. Indian exporters seeking to supply DiaSys Diagnostic Systems GmbH must ensure their manufacturing facilities meet these rigorous GMP requirements and that they possess the necessary import licenses to distribute their products within Germany.

Diasys Diagnostic Systems Gmbh — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

DiaSys Diagnostic Systems GmbH's focus on diagnostic products, particularly in the categories of medical devices and diagnostics, reflects a strategic emphasis on providing essential tools for clinical laboratories. The market demand for reliable and efficient diagnostic solutions drives the importation of these products. By concentrating on these therapeutic areas, DiaSys aims to meet the critical needs of healthcare providers and patients, ensuring accurate and timely diagnoses.

2Sourcing Profile

DiaSys Diagnostic Systems GmbH's sourcing strategy for generic drugs involves importing finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, from India. This approach allows DiaSys to offer a diverse range of diagnostic products without the complexities associated with raw API procurement. India's established pharmaceutical manufacturing capabilities and cost-effectiveness make it a strategic partner for DiaSys in sourcing these formulations.

3Market Positioning

Based on its product mix, DiaSys Diagnostic Systems GmbH serves the clinical laboratory segment within the German market. Their offerings are tailored to meet the needs of hospitals, diagnostic centers, and other healthcare facilities requiring high-quality diagnostic reagents and systems. By focusing on this segment, DiaSys positions itself as a key supplier of diagnostic solutions essential for patient care.

Seller's Guide — How to Become a Supplier to Diasys Diagnostic Systems Gmbh

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the German market by meeting DiaSys Diagnostic Systems GmbH's quality standards and regulatory requirements. Gaps in DiaSys's current sourcing, such as the potential for diversification of suppliers, could be addressed by Indian exporters offering competitive and compliant products. Establishing a relationship with DiaSys could provide Indian suppliers with access to the European market and enhance their global presence.

2Requirements & Qualifications

Indian exporters seeking to supply DiaSys Diagnostic Systems GmbH and the German market must ensure their manufacturing facilities comply with EU GMP standards. They must possess the necessary import licenses and adhere to German labeling and serialization requirements. Additionally, products must undergo batch testing and stability studies to meet regulatory standards. Ensuring these qualifications will facilitate entry into the German market and establish credibility with German importers.

3How to Approach

Frequently Asked Questions — Diasys Diagnostic Systems Gmbh

What products does Diasys Diagnostic Systems Gmbh import from India?

Diasys Diagnostic Systems Gmbh imports 4 pharmaceutical products across 3 categories. Top imports: Diagnostic ($950.5K), Reagent ($950.5K), Serum ($339.0K), Protein ($280.1K).

Who supplies pharmaceuticals to Diasys Diagnostic Systems Gmbh from India?

Diasys Diagnostic Systems Gmbh sources from 1 verified Indian suppliers. The primary supplier is Advy Chemical Private Limited (100.0% of imports, $824.4K).

What is Diasys Diagnostic Systems Gmbh's total pharmaceutical import value?

Diasys Diagnostic Systems Gmbh's total pharmaceutical import value from India is $2.5M, based on 123 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Diasys Diagnostic Systems Gmbh focus on?

Diasys Diagnostic Systems Gmbh imports across 3 categories. The largest: Medical Devices & Diagnostics (75.4%), Other (13.5%), Nutritional Supplements (11.1%).

Get Full Diasys Diagnostic Systems Gmbh Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.